We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-19.74%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2B
AUM Growth
+$181M
Cap. Flow
-$182M
Cap. Flow %
-9.13%
Top 10 Hldgs %
62.34%
Holding
416
New
102
Increased
87
Reduced
79
Closed
120

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$21.3M
2
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$21.2M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$16.1M
4
BIIB icon
Biogen
BIIB
+$9.79M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$8.84M

Top Sells

Rank Stock Value
1
IWM icon
iShares Russell 2000 ETF
IWM
+$33.1M
2
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$7.45M
3
MBLY
Mobileye N.V.
MBLY
+$7.26M
4
TBRA
Tobira Therapeutics, Inc. Common Stock
TBRA
+$5.86M
5
ASXC
Asensus Surgical, Inc.
ASXC
+$5.01M

Sector Composition

Rank Sector Weight
1 Healthcare 11.94%
2 Consumer Staples 0.06%
3 Industrials 0.04%
4 Technology 0.04%
5 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GBT
26
CALL
DELISTED
Global Blood Therapeutics, Inc.
GBT
$8.92M 0.45%
+5,627
New +$100K
ABBV icon
27
PUT
AbbVie
ABBV
$458B
$8.83M 0.44%
1,546
-906
-37% -$50.5K
TVTX icon
28
PUT
Travere Therapeutics
TVTX
$5.33B
$8.54M 0.43%
+6,251
New +$94.8K
UTHR icon
29
CALL
United Therapeutics
UTHR
$26.3B
$8.36M 0.42%
750
-28
-4% -$3.54K
RGLS
30
CALL
DELISTED
Regulus Therapeutics
RGLS
$8.11M 0.41%
98
-2
-2% -$1.59K
ESRX
31
PUT
DELISTED
Express Scripts Holding Company
ESRX
$7.31M 0.37%
+1,064
New +$76.5K
LNKD
32
CALL
DELISTED
LinkedIn Corporation
LNKD
$6.62M 0.33%
+579
New +$85.1K
PTLA
33
CALL
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$6.57M 0.33%
3,221
+3,104
+2,653% +$98.5K
GWPH
34
PUT
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$6.55M 0.33%
908
-2,275
-71% -$125K
ANAC
35
CALL
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$6.49M 0.32%
1,214
+26
+2% +$1.92K
ASRT
36
CALL
DELISTED
Assertio
ASRT
$5.86M 0.29%
70
+4
+6% +$3.71K
TENX icon
37
Tenax Therapeutics
TENX
$385M
$5.68M 0.28%
87
+3
+4% +$233K
BPMC
38
CALL
DELISTED
Blueprint Medicines
BPMC
$5.42M 0.27%
3,000
– –
ACAD icon
39
CALL
Acadia Pharmaceuticals
ACAD
$4.25B
$5.14M 0.26%
1,840
+351
+24% +$7.65K
ABUS icon
40
Arbutus Biopharma
ABUS
$865M
$4.95M 0.25%
1,197,338
+197,338
+20% +$705K
TVTX icon
41
CALL
Travere Therapeutics
TVTX
$5.33B
$4.94M 0.25%
+3,617
New +$54.9K
LXRX icon
42
CALL
Lexicon Pharmaceuticals
LXRX
$1.02B
$4.89M 0.24%
4,092
+1,357
+50% +$14.2K
NWBO
43
DELISTED
Northwest Biotherapeutics, Inc. Common stock
NWBO
$4.84M 0.24%
3,317,519
+2,399,577
+261% +$4.73M
ALXN
44
PUT
DELISTED
Alexion Pharmaceuticals
ALXN
$4.76M 0.24%
342
-633
-65% -$92.9K
ELDN icon
45
Eledon Pharmaceuticals
ELDN
$276M
$4.56M 0.23%
+5,014
New +$4.92M
VRTX icon
46
CALL
Vertex Pharmaceuticals
VRTX
$121B
$4.37M 0.22%
550
+209
+61% +$18.9K
IRD
47
Opus Genetics
IRD
$254M
$4.36M 0.22%
+27,526
New +$4.58M
EIGR
48
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$4.35M 0.22%
+8,655
New +$4.31M
ZGNX
49
CALL
DELISTED
Zogenix, Inc.
ZGNX
$4.29M 0.21%
4,639
-10,543
-69% -$106K
DVAX
50
DELISTED
Dynavax Technologies
DVAX
$4.23M 0.21%
220,000
+100,000
+83% +$2.02M
1
2
3 4 5

Similar funds

NA
Novus Advisors Greenville, South Carolina $44.7M AUM 18.41% 1-Year Est. Return
CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Sabby Management's Q1 2016 Portfolio in Review

As of Q1 2016, Sabby Management held 416 positions worth $2B, up 9.9% from $1.82B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Sabby Management withdrew a net $182M in Q1 2016, closing 120 positions and reducing 79 holdings. Its most notable exit was iShares Russell 2000 ETF, an estimated $33.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 12% of assets, up from 10% a quarter earlier, followed by Consumer Staples and Industrials.

Against the trend, Sabby Management opened a new position in Amgen worth $21.5M.

  • Sabby Management's largest Q1 2016 buy was Amgen: 143,486 shares worth $21.5M.
  • Sabby Management added most to Northwest Biotherapeutics, Inc. Common stock in Q1 2016, an estimated $4.73M increase.
  • Sabby Management's biggest Q1 2016 reduction was GW Pharmaceuticals Plc American Depositary Shares, cutting an estimated $7.45M.
  • Sabby Management fully exited iShares Russell 2000 ETF in Q1 2016, selling an estimated $33.1M.
  • Sabby Management's ten largest holdings make up 62% of its $2B portfolio in Q1 2016.
  • Sabby Management opened 102 new positions and closed 120 in Q1 2016.
  • Sabby Management's portfolio value rose 9.9% quarter-over-quarter to $2B.

Based on Sabby Management's 13F filing for Q1 2016, filed 13 May 2016.